Start here if you're new
what it is
Incyte sells cancer and inflammation drugs, collects royalties, and uses that cash to fund its next wave of treatments.
how it gets paid
Last year Incyte made $5.1B in revenue.
why it's growing
Revenue grew 21.2% last year. The 19.2% EPS beat mattered most because it showed the business is outrunning expectations even after a year with messy comparison points.
what just happened
Incyte delivered $1.80 EPS versus $1.51 expected, a 19.2% beat.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
10/100 earnings predictability — expect surprises
14.9x trailing p/e — the market's not buying it — or you found a deal
25.5% return on capital — every dollar works hard here
xvary composite: 57/100 — below average
What they do
Incyte sells cancer and inflammation drugs, collects royalties, and uses that cash to fund its next wave of treatments.
This is not biotech cosplay. Incyte turned $5.1 billion of revenue into a 29.5% operating margin and a 25.5% return on capital (money invested in the business → profit earned on it → each dollar goes to work hard). You care because that cash funds new trials and launches without the usual biotech begging bowl.
How they make money
$5.1B
annual revenue · their business grew +21.2% last year
total revenue
$5.1B
+21.2%
The products that matter
hematology franchise
Jakafi
$3.1B revenue
it's still the center of gravity. A $3.1B drug with 2028 patent exposure is both the profit engine and the valuation overhang.
the current cash machine
dermatology growth drug
Opzelura
$750–$790M 2026 guide
this is the handoff story. Management guided to $750–$790M for 2026, which is real growth but still below the $800M+ the market had penciled in.
replacement candidate
newer launches and pipeline
Niktimvo, Monjuvi and pipeline
supports $4.77–$4.94B outlook
the data here is light on individual sales, which tells you something by itself. These programs matter because management is leaning on them to support 2026 revenue as Jakafi's 2028 deadline gets closer.
what has to scale next
Key numbers
$7.0B
2029 revenue
Revenue is projected to rise from $5.1 billion to $7.0 billion. That is the bridge between a cheap stock today and a bigger earnings base later.
14.9x
trailing p/e
P/E ratio → how many dollars investors pay for one dollar of profit → you are paying a market-like multiple for a company with 30.6% net margin.
29.5%
operating margin
Operating margin → profit after running the business → nearly 30 cents of every sales dollar stays before interest and taxes.
0.7
beta
Beta → how jumpy the stock is versus the market → Incyte has been calmer than the average biotech name.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 70 / 100
- net profit margin 30.6% — keeps 31 cents of every dollar in revenue
- return on equity 26% — $0.26 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in INCY 3 years ago → it's now worth $12,620.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Incyte delivered $1.80 EPS versus $1.51 expected, a 19.2% beat.
The latest quarter showed revenue of $3.6 billion, up 166% vs. prior year, while EPS reached $4.95, up 135%. Management also said product, royalty, and milestone revenue all added to the top line.
$1.3B
revenue
$4.95
eps
+166%
revenue growth
the number that mattered
The 19.2% EPS beat mattered most because it showed the business is outrunning expectations even after a year with messy comparison points.
-
incyte corp. reported 2025 financial results.the company delivered double-digit revenue increases during the fourth quarter and the full year, to $1.51 billion and $5.14 billion, respectively.
-
all three revenue sources (product, royalty, and milestone) contributed to the top line.share earnings registered at $1.80 and $6.80, respectively, in the december and full-year time frames.
-
vs. prior year comparisons are difficult since we are now presenting earnings on an adjusted basis.
-
the company’s near-term prospects appear solid.
-
incyte enters 2026 having achieved milestone progress and gaining several regulatory approvals.approvals were obtained in some european countries, and japan for monjuvi, which complements incyte’s hematology portfolio. also, the u.s. launch of niktimvo, used for the treatment of chronic graftversus-host disease, has been going well. these additions, along with existing medicines, ought to drive healthy revenue and share-earnings progress in 2026 and 2027.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
this story breaks if the $3.1B Jakafi base starts looking closer than the replacement plan.
med
Jakafi exclusivity ends
Jakafi produced $3.1B last year. When exclusivity weakens in 2028, that revenue base becomes contestable fast.
This is the core earnings engine today. If erosion starts before newer assets scale, the low multiple will look rational, not pessimistic.
med
Opzelura misses its own handoff job
Management guided Opzelura to $750–$790M in 2026, already below the $800M+ many investors expected.
If the supposed replacement drug keeps missing the market's internal model, the stock keeps trading like a business heading toward a hole in the income statement.
med
New launches stay encouraging but small
Monjuvi, Niktimvo and the broader pipeline matter more because Jakafi's timetable is visible. The page data is light on their current revenue contribution, which means the proof still has to show up in reported numbers.
Clinical setbacks, slower launches, or weak uptake would leave too much of the $4.77–$4.94B 2026 plan resting on one mature asset.
med
Adjusted comparisons blur the trend
The page data says prior-year comparisons are harder because results are now presented on an adjusted basis.
That does not change the business, but it does raise the odds that investors disagree on how clean the progress really is. When predictability is already 10/100, that matters.
Jakafi generated $3.1B last year, so the risk is not abstract. If the handoff drags, the patent calendar turns from a future issue into the present valuation story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
Opzelura versus the $750–$790M guide
This is the replacement story in one line. If this number starts landing above expectations, the whole debate changes.
calendar
the 2028 Jakafi deadline
Every quarter that passes without a clearer revenue handoff makes the patent clock louder.
trend
whether 2026 revenue moves above $4.94B
The high end of management's own guide is the first line the market wants to see cleared.
risk
proof that newer launches are material
Monjuvi and Niktimvo sound encouraging. You want that optimism to show up in reported sales, not just commentary.
Analyst rankings
short-term outlook
average
momentum score 3 — the stock is acting like the broader market, not breaking away from the patent debate.
risk profile
average
stability score 3 — in human-speak, analysts see a normal risk profile for a profitable biotech, not a bunker stock.
chart momentum
top 20%
technical score 2 — better-than-average price action in the near term, even with the handoff question still unresolved.
earnings predictability
10 / 100
earnings are hard to model here. launch pace, pipeline timing and milestone noise all matter.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 376 buyers vs. 288 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$85
$180
$101
current price
$133
target midpoint · +32% from current · 3-5yr high: $160 (+60% · 12% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive